Hepatitis C Therapy - Schering-Plough Drug Gets Fast Track

Schering-Plough Drug Gets Fast Track
MSN MoneyCentral - KENILWORTH, N.J. (AP) - Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment. The Food and Drug Administration gives the fast track label -- which sometimes helps speed the

Novartis And Idenix Seek European Approval Of Telbivudine (LDT600) For
Medical News Today - Novartis and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than

FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH
Medical News Today - Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment

Viral Hepatitis and HIV Coinfection
Medscape News - In Western countries, chronic HBV infection affects 5% to 10% of HIV-positive individuals. However, a larger proportion of the HIV-infected population has been exposed to HBV in the past. Isolated hepatitis B core antibody (anti-HBc) is more common